{
    "title": "107_s961",
    "content": "The Act is titled the \"Breast Implant Research and Information Act\" and its purpose is outlined in the findings section. The findings section highlights the lack of a patient registry for breast implant recipients, the high number of women receiving breast implants, the adverse reaction reports received by the FDA, and the importance of providing complete and accurate information to women considering breast implants. Silicone breast implants were never approved by the FDA, while saline breast implants were approved in 2000 despite high complication rates. A criminal investigation was opened in 1998 due to allegations of research data manipulation by a breast implant manufacturer. Women need accurate information on breast implant risks to make informed decisions. In 1998, the FDA investigated a breast implant manufacturer for manipulating research data. Despite this, saline breast implants were approved in 2000. Studies show high rates of complications, with 1 in 4 women needing additional surgery within 5 years. Research in 2000 found that 70% of women with implants had at least one rupture after 10-15 years. In 2000, research sponsored by the FDA found that 70% of women with breast implants had at least one rupture after 10-15 years. Silicone migration was observed in 21% of women, with unknown implications for disease development. A 1993 study suggested that silicone breast implants could lead to serious immunological implications. The safety of silicone breast implants has been a topic of concern. Research has shown that these implants are not immunologically inert and may lead to serious implications. Studies have found higher rates of complications, including silicone migration and increased risk of cancer, in women with breast implants. Implant recipients with silicone breast implants may suffer from higher rates of lung and brain cancer. Research has shown evidence of silicone migration in women with ruptured implants, leading to severe inflammation and complications. The presence of implants can also make mammograms less accurate, delaying the detection of breast cancer. The curr_chunk discusses the difficulties in obtaining accurate mammograms due to silicone breast implants masking up to 40% of breast tissue, potentially delaying early breast cancer detection. It also highlights concerns about the negative impact of implants on breastfeeding and calls for research on the health effects of breast implants. The curr_chunk emphasizes the importance of providing accurate information about breast implants to women and urges the FDA to investigate allegations of wrongdoing by a manufacturer. It clarifies that the Act does not affect existing regulations on silicone breast implants for reconstruction, correction of deformities, or replacement. The Director of the National Institutes of Health will update Congress on existing breast implant research within 90 days. A new section on breast implant research is added to the Public Health Service Act. The Director of NIH appoints a coordinator for breast implant research, involving various Institutes. Study sections are established to review grant applications for appropriate design. The Director of NIH appoints a coordinator for breast implant research and establishes study sections to review grant applications for appropriate design. The NIH conducts research to understand the health implications of saline and silicone breast implants, including a clinical study of women with implants for at least eight years. A study on women with breast implants for at least eight years should differentiate between mastectomy, reconstructive, and cosmetic purposes, as well as saline and silicone implants. It should focus on local complications like capsular contracture, leakage, and rupture, as well as atypical symptoms, silicone migration, and immune system irregularities. The Director of NIH will submit an annual report on the study's results to Congress. The Food and Drug Administration will intensify postmarket research on saline breast implants based on recommendations from their panel. The Commissioner of Food and Drugs will report to Congress on the implementation status of these recommendations at regular intervals. Additionally, activities regarding silicone breast implants will be expanded and intensified at the FDA. To ensure accurate information about silicone breast implants, the Commissioner of Food and Drugs will expedite investigations into wrongdoing, update consumer information materials, and require manufacturers to regularly update package inserts with correct implant information. The FDA will require manufacturers of silicone breast implants to update package inserts and informed consent documents regularly to provide accurate information on complications and ruptures. Manufacturers conducting clinical studies must provide patients with FDA's breast implant booklet and ensure informed consent documents are given at the initial consultation. Women should be informed about how to obtain a Medwatch form. The FDA mandates manufacturers of silicone breast implants to update package inserts and informed consent documents regularly. Clinical studies must provide patients with the FDA's breast implant booklet and inform women about obtaining a Medwatch form. Additionally, a special patient panel reviews breast implant information and advertisements for accuracy. The FDA mandates manufacturers to update breast implant information regularly. A special patient panel reviews this information annually to ensure accuracy and includes various experts and recipients."
}